# Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch

> **NCT01902992** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 202 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis

## Interventions

- **DRUG:** Depiquick Birch (DPG103)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01902992
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2017-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01902992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01902992, "Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01902992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*